18F-FDG positron emission tomography ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study
Auteur(s) :
Ledoult, Emmanuel [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Morelle, Maxime [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Soussan, Michael [Auteur]
Hôpital Avicenne [AP-HP]
Mékinian, Arsène [Auteur]
CHU Saint-Antoine [AP-HP]
Béhal, Hélène [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Sobanski, Vincent [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Hachulla, Eric [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Huglo, Damien [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Le Gouellec, Noémie [Auteur]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Centre hospitalier [Valenciennes, Nord]
Remy-Jardin, Martine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Baillet, Clio [Auteur]
Recherche translationelle relations hôte-pathogènes
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Launay, David [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Morelle, Maxime [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Soussan, Michael [Auteur]
Hôpital Avicenne [AP-HP]
Mékinian, Arsène [Auteur]
CHU Saint-Antoine [AP-HP]
Béhal, Hélène [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Sobanski, Vincent [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Hachulla, Eric [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Huglo, Damien [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Le Gouellec, Noémie [Auteur]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Centre hospitalier [Valenciennes, Nord]
Remy-Jardin, Martine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Baillet, Clio [Auteur]
Recherche translationelle relations hôte-pathogènes
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Launay, David [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE (Ex-Liric)]
Centre de référence des maladies auto-immunes systémiques rares du Nord et Nord Ouest [CHRU Lille]
Titre de la revue :
Arthritis research & therapy
Pagination :
76
Éditeur :
BMC
Date de publication :
2021-03-06
ISSN :
1478-6362
Mot(s)-clé(s) en anglais :
18F-FDG PET/CT
Interstitial lung disease
Pulmonary function tests
Systemic sclerosis
18 F-FDG PET/CT
Interstitial lung disease
Pulmonary function tests
Systemic sclerosis
18 F-FDG PET/CT
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background: Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that ...
Lire la suite >Background: Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool in the managing of SSc-ILD.Methods: In our center, SSc patients and controls (non-Hodgkin lymphoma cured after first-line regimen) who had received a PET/CT were screened retrospectively. The FDG uptake (visual intensity, pattern, SUVmax) was systematically recorded in > 30 regions of interest (ROIs) linked to SSc in a blind reviewing by 2 independent nuclear medicine physicians using a standardized form.Results: Among the 545 SSc patients followed up in our center, 36, including 22 SSc-ILDs, had a PET/CT, whose indication was cancer screening in most cases. The mean ± SD age was 57.9 ± 13.0 years with 20/36 females. Fourteen patients had a disease duration of less than 2 years. A third had anti-centromere antibodies and 27.8% had anti-topoisomerase antibodies. Pulmonary FDG uptakes were higher in SSc patients than in controls (n = 89), especially in those with ILD compared with those without ILD. Pulmonary FDG uptakes were positively correlated with the ILD severity (fibrosis extent, %FVC, and %DLCO). No significant difference was found in the FDG uptakes from extrathoracic ROIs. Progressing SSc-ILDs within the 2 years after PET/CT (n = 9) had significant higher pulmonary FDG uptakes at baseline than stable SSc-ILDs (n = 13).Conclusion: PET/CT could be a useful tool in the assessment of the severity and the prediction of pulmonary function outcome of SSc-ILD.Lire moins >
Lire la suite >Background: Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the 18F-FDG tracer could be a tool in the managing of SSc-ILD.Methods: In our center, SSc patients and controls (non-Hodgkin lymphoma cured after first-line regimen) who had received a PET/CT were screened retrospectively. The FDG uptake (visual intensity, pattern, SUVmax) was systematically recorded in > 30 regions of interest (ROIs) linked to SSc in a blind reviewing by 2 independent nuclear medicine physicians using a standardized form.Results: Among the 545 SSc patients followed up in our center, 36, including 22 SSc-ILDs, had a PET/CT, whose indication was cancer screening in most cases. The mean ± SD age was 57.9 ± 13.0 years with 20/36 females. Fourteen patients had a disease duration of less than 2 years. A third had anti-centromere antibodies and 27.8% had anti-topoisomerase antibodies. Pulmonary FDG uptakes were higher in SSc patients than in controls (n = 89), especially in those with ILD compared with those without ILD. Pulmonary FDG uptakes were positively correlated with the ILD severity (fibrosis extent, %FVC, and %DLCO). No significant difference was found in the FDG uptakes from extrathoracic ROIs. Progressing SSc-ILDs within the 2 years after PET/CT (n = 9) had significant higher pulmonary FDG uptakes at baseline than stable SSc-ILDs (n = 13).Conclusion: PET/CT could be a useful tool in the assessment of the severity and the prediction of pulmonary function outcome of SSc-ILD.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :
Fichiers
- https://hal.sorbonne-universite.fr/hal-03268481/document
- Accès libre
- Accéder au document
- https://hal.sorbonne-universite.fr/hal-03268481/file/s13075-021-02460-8.pdf
- Accès libre
- Accéder au document
- https://hal.sorbonne-universite.fr/hal-03268481/document
- Accès libre
- Accéder au document
- https://hal.sorbonne-universite.fr/hal-03268481/file/s13075-021-02460-8.pdf
- Accès libre
- Accéder au document
- https://hal.sorbonne-universite.fr/hal-03268481/document
- Accès libre
- Accéder au document
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7936499/pdf
- Accès libre
- Accéder au document
- https://hal.sorbonne-universite.fr/hal-03268481/document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- s13075-021-02460-8.pdf
- Accès libre
- Accéder au document
- Accès libre
- Accéder au document